Hikma Pharmaceuticals could regain its upward trend after having run out of steam.

The company shows strong fundamentals. The revenues is expected to double in the next 5 years, which show a good long term vision of the group. In addition, the consensus revised upward EPS estimates for this year and that let see a great potential for the security on the stock market.

Technically, the uptrend in the medium and long term should protect the stock of a major downtrend. In the short term, a decline has led the share to the GBp 1000 support. Therefore, a technical rebound, already launched, will fix an objective near the GBp 1066 short-term resistance.

The GBp 1000 area represent an interesting purchase level to target GBp 1066, and by extension the GBp 1112. A stop loss will be fixed below the entry point to limit the risk.